IL6 and breast carcinoma: The emerging role of IL-6/JAK/STAT3 in promoting the breast CSC subpopulation and breast cancer metastases in vivo underscores the therapeutic potential in exploiting the IL-6/JAK/STAT3 signaling axis in metastatic breast cancer.